Cargando…

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)

The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large‐cell lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xue, Shao, Yun, Qin, Hai‐Feng, Tai, Yan‐Hong, Gao, Hong‐Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879058/
https://www.ncbi.nlm.nih.gov/pubmed/29488330
http://dx.doi.org/10.1111/1759-7714.12613
_version_ 1783310927094874112
author Du, Xue
Shao, Yun
Qin, Hai‐Feng
Tai, Yan‐Hong
Gao, Hong‐Jun
author_facet Du, Xue
Shao, Yun
Qin, Hai‐Feng
Tai, Yan‐Hong
Gao, Hong‐Jun
author_sort Du, Xue
collection PubMed
description The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large‐cell lymphoma. Since then, ALK has been associated with other types of cancers, including non‐small‐cell lung cancer (NSCLC). More than 19 different ALK fusion partners have been discovered in NSCLC, including EML4, KIF5B, KLC1, and TPR. Most of these ALK fusions in NSCLC patients respond well to the ALK inhibitor, crizotinib. In this paper, we reviewed fusion partner genes with ALK, detection methods for ALK‐rearrangement (ALK‐R), and the ALK‐tyrosine kinase inhibitor, crizotinib, used in NSCLC patients.
format Online
Article
Text
id pubmed-5879058
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-58790582018-04-04 ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC) Du, Xue Shao, Yun Qin, Hai‐Feng Tai, Yan‐Hong Gao, Hong‐Jun Thorac Cancer Invited Review The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large‐cell lymphoma. Since then, ALK has been associated with other types of cancers, including non‐small‐cell lung cancer (NSCLC). More than 19 different ALK fusion partners have been discovered in NSCLC, including EML4, KIF5B, KLC1, and TPR. Most of these ALK fusions in NSCLC patients respond well to the ALK inhibitor, crizotinib. In this paper, we reviewed fusion partner genes with ALK, detection methods for ALK‐rearrangement (ALK‐R), and the ALK‐tyrosine kinase inhibitor, crizotinib, used in NSCLC patients. John Wiley & Sons Australia, Ltd 2018-02-28 2018-04 /pmc/articles/PMC5879058/ /pubmed/29488330 http://dx.doi.org/10.1111/1759-7714.12613 Text en © 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Invited Review
Du, Xue
Shao, Yun
Qin, Hai‐Feng
Tai, Yan‐Hong
Gao, Hong‐Jun
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
title ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
title_full ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
title_fullStr ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
title_full_unstemmed ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
title_short ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
title_sort alk‐rearrangement in non‐small‐cell lung cancer (nsclc)
topic Invited Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879058/
https://www.ncbi.nlm.nih.gov/pubmed/29488330
http://dx.doi.org/10.1111/1759-7714.12613
work_keys_str_mv AT duxue alkrearrangementinnonsmallcelllungcancernsclc
AT shaoyun alkrearrangementinnonsmallcelllungcancernsclc
AT qinhaifeng alkrearrangementinnonsmallcelllungcancernsclc
AT taiyanhong alkrearrangementinnonsmallcelllungcancernsclc
AT gaohongjun alkrearrangementinnonsmallcelllungcancernsclc